Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2019 16:05 ET | Source: Anchiano Therapeutics

Anchiano Therapeutics Chairman Stephen Hoffman Steps Down from Board

CAMBRIDGE, Mass., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano” or the “Company”), a pivotal-stage biopharmaceutical company focused on the discovery and...
September 23, 2019 17:03 ET | Source: Anchiano Therapeutics

Anchiano Therapeutics Enters into An Exclusive Option To License Agreement for Novel Pan-RAS Inhibitor and PDE10/β-catenin Inhibitor Programs

Anchiano will make an upfront payment in exchange for the option to in-license at any time through obtaining an Investigational New Drug (IND) designation Company also provides update on accrual to...
September 20, 2019 08:30 ET | Source: Anchiano Therapeutics

Anchiano Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

CAMBRIDGE, Mass., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of...
September 03, 2019 08:00 ET | Source: Anchiano Therapeutics

Anchiano Therapeutics to Present at the Baird 2019 Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of...
August 05, 2019 17:15 ET | Source: Anchiano Therapeutics

Anchiano Therapeutics Reports Second Quarter 2019 Financial Results

CAMBRIDGE, Mass., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of...
June 18, 2019 08:30 ET | Source: Anchiano Therapeutics

Anchiano Therapeutics Delists Ordinary Shares from the Tel Aviv Stock Exchange

CAMBRIDGE, Mass., June 18, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of...
May 29, 2019 08:30 ET | Source: Anchiano Therapeutics

Anchiano Therapeutics Announces Appointment of Salar Roshan as Head of Business Development

CAMBRIDGE, Mass., May 29, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development...
May 22, 2019 09:00 ET | Source: Anchiano Therapeutics

Anchiano Therapeutics Reports First Quarter 2019 Financial Results

– Closed $30.5 million U.S. Initial Public Offering in February 2019 – CAMBRIDGE, Mass., May 22, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”), a...
March 14, 2019 17:42 ET | Source: Anchiano Therapeutics

Anchiano Therapeutics to Present at the Oppenheimer 29th Annual Healthcare Conference

CAMBRIDGE, Mass., March 14, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and...
March 14, 2019 08:16 ET | Source: Anchiano Therapeutics

Anchiano Therapeutics Initiates Process to Voluntarily Delist its Ordinary Shares from the Tel Aviv Stock Exchange

CAMBRIDGE, Mass., March 14, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”) today announced an update with respect to its intention to voluntarily delist its...